Thank you, Mr. Chair.
This is a critical issue. I find it interesting that in the conclusions it says that Bill C-393 would not overcome the systemic issues of health care delivery and disease prevention in the developing world.
That's almost an absurd statement. I don't know of any organization, group, or interested party that has ever made that claim. Nobody here is saying that this will be the one single solution to human suffering. At the same time, we have a bill that Parliament passed that has only been triggered once. I suppose we have a Parliament that likes to set up legislation that doesn't work or isn't used. We spent a lot of time and money on this, so there's a problem here.
Ms. Downie, you almost indicated that if this is changed, we're going to have all kinds of generic drugs flying out across the world and not be able to track them. But the reality is that the generic drugs must have different markings and different packaging. It has to be stated what country they're going to and the quantity.
What other mechanisms are necessary to protect? You would have a company publicly doing something fraudulent out there. What is the real risk? I don't understand, especially given the Rwanda situation, where we had one out there. What is the threat here? They're still going to be identified, the company still has to identify where they're going, and they're going to be tracked.